Parametric Portfolio Associates LLC lifted its stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 17.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,796 shares of the biopharmaceutical company’s stock after acquiring an additional 6,970 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Juno Therapeutics were worth $1,399,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. UBS Asset Management Americas Inc. increased its holdings in Juno Therapeutics by 76.4% in the first quarter. UBS Asset Management Americas Inc. now owns 29,900 shares of the biopharmaceutical company’s stock valued at $663,000 after buying an additional 12,947 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Juno Therapeutics by 2,185.8% in the first quarter. JPMorgan Chase & Co. now owns 62,746 shares of the biopharmaceutical company’s stock valued at $1,393,000 after buying an additional 60,001 shares during the last quarter. Teachers Advisors LLC increased its holdings in Juno Therapeutics by 5.8% in the first quarter. Teachers Advisors LLC now owns 64,365 shares of the biopharmaceutical company’s stock valued at $1,428,000 after buying an additional 3,531 shares during the last quarter. Legal & General Group Plc increased its holdings in Juno Therapeutics by 220.6% in the first quarter. Legal & General Group Plc now owns 25,858 shares of the biopharmaceutical company’s stock valued at $574,000 after buying an additional 17,792 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Juno Therapeutics by 5.2% in the first quarter. Vanguard Group Inc. now owns 6,153,812 shares of the biopharmaceutical company’s stock valued at $136,553,000 after buying an additional 303,912 shares during the last quarter. 66.71% of the stock is currently owned by institutional investors and hedge funds.
Several research firms recently commented on JUNO. Zacks Investment Research lowered Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Morgan Stanley increased their target price on Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a report on Monday, August 7th. Maxim Group reissued a “buy” rating and issued a $56.00 target price on shares of Juno Therapeutics in a report on Thursday, November 2nd. Vetr lowered Juno Therapeutics from a “hold” rating to a “sell” rating and set a $28.47 target price on the stock. in a report on Monday, August 7th. Finally, Cowen and Company reissued a “buy” rating and issued a $49.00 target price on shares of Juno Therapeutics in a report on Friday, October 27th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $44.20.
TRADEMARK VIOLATION WARNING: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/15/parametric-portfolio-associates-llc-buys-6970-shares-of-juno-therapeutics-inc-juno.html.
Juno Therapeutics, Inc. (NASDAQ:JUNO) opened at $53.86 on Wednesday. Juno Therapeutics, Inc. has a twelve month low of $17.52 and a twelve month high of $61.59. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.
Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the prior year, the firm earned ($0.57) earnings per share. The business’s quarterly revenue was up 115.4% compared to the same quarter last year. equities research analysts predict that Juno Therapeutics, Inc. will post -4.02 earnings per share for the current year.
In other news, EVP Robert Azelby sold 12,869 shares of the stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $39.95, for a total transaction of $514,116.55. Following the completion of the sale, the executive vice president now owns 50,289 shares in the company, valued at $2,009,045.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sunil Agarwal sold 7,285 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Insiders have sold 79,670 shares of company stock valued at $3,553,777 in the last quarter. Insiders own 15.26% of the company’s stock.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.